Covariate | Crude odds ratio | 95% confidence interval | P | Adjusted odds ratio^{a} | 95% confidence interval | P |
---|---|---|---|---|---|---|
IGF-I levels | ||||||
<97.4 | 1.00 | 1.00 | ||||
97.4–119.1 | 0.71 | 0.5–1.0 | 0.04 | 0.69 | 0.5–1.0 | 0.05 |
119.2–150.2 | 0.71 | 0.5–1.0 | 0.04 | 0.73 | 0.5–1.1 | 0.09 |
>150.2 | 0.69 | 0.5–0.9 | 0.03 | 0.67 | 0.5–0.9 | 0.04 |
IGFBP-3 levels | ||||||
>2636.6 | 1.00 | 1.00 | ||||
2308.8–2636.6 | 0.81 | 0.6–1.2 | 0.25 | 0.79 | 0.5–1.2 | 0.24 |
1967.0–2308.7 | 1.14 | 0.8–1.6 | 0.46 | 1.02 | 0.7–1.5 | 0.91 |
<1967.0 | 1.29 | 0.9–1.8 | 0.14 | 1.27 | 0.9–1.2 | 0.21 |
^{a} Each genetic marker assumed to be independent. Thus, each genetic marker adjusted for age, PSA, free:total prostate-specific antigen (PSA) ratio, digital rectal exam (DRE), ethnicity, family history and obstructive voiding symptoms. IGF-1 and IGFBP-3 considered together in a multivariate model adjusting for age, PSA, free:total PSA ratio, DRE, ethnicity, family history and obstructive voiding symptoms.
^{b} CAG repeat units also considered as continuous variable. Adjusted odds ratio = 1.01 for prostate cancer per CAG repeat unit increase (95% confidence interval, 0.97–1.05; P = 0.57).